Cell>Pont’s principal focus is chelation based metabolic imaging and intra-nuclear target specific therapy for oncology, cardiology including stroke, diabetes, neuroendocrine, and ischemic based diseases. Since 2001, Cell>Point has in-licensed five technology platforms from The University of Texas M.D. Anderson Cancer Center (M.D. Anderson) and is currently developing an array of compounds for commercialization. The company’s lead drug conjugate compound, Oncardia®, is in a Phase 3 lung cancer imaging trial under an FDA approved Special Protocol Assessment (“SPA”), and a Phase 2b trial to diagnose the presence and extent of coronary artery disease focusing specifically on myocardial ischemia in patients who have suffered a myocardial infarction. In therapy, the company is conducting preclinical studies on its first two compounds, Platinum-Oncardia® and 187Re-Oncardia®, for the treatment of the relapsed stage of aggressive diffuse type B-cell lymphoma.
The company owns majority interest in Vyripharm Biopharmaceuticals which has in-licensed the company’s In-Situ Hydrogel, N4 and Oligosaccharide (Dual Agent) Technologies to carry forward research and development activities involving products from the three platforms. One of Vyripharm’s chief strengths is in its cannabinoid research. Vyripharm will be developing applications using these product technologies in combination with cannabinoids for nuclear imaging and therapeutic applications for neurologic disorders including, but not limited to, post-traumatic stress disorder (“PTSD”), epilepsy and other acute/chronic disorders through sponsored research relationships with five healthcare institutions in the Texas Medical Center and Galveston Texas. In addition to the aforementioned work, Vyripharm has established a proprietary comprehensive analytical testing, monitoring and tracking system program that it believes will become the standard accepted methodology to help create stability and predictability in the emerging business of medical cannabinoids as states continue to move forward with efforts to legalize medical cannabis. Vyripharm is located in the Texas Medical Center in Houston, Texas
All of Cell>Pont’s platform technologies including the three platforms licensed to Vyripharm have patents issued or pending in 44 countries. Cell>Point is currently pursuing out-licensing the rights to Oncardia® in those countries and has completed licenses for Oncardia® in Brazil, South Korea and China.
Cell>Point is privately held with offices in Colorado and Texas.
Corporate Email Policy: All corporate emails are retained for 30 days
Cell>Point is managed by its three founding partners. The founders of the Company have extensive experience in molecular biology, molecular imaging and oncology, health care acquisitions and investment banking, health care marketing and legal. Cell>Point utilizes an extensive network of consultants, strategic partners, including Philips Healthcare, and sponsored research with M.D. Anderson.
Managing Member & President/CEO
Greg Colip is a founding member of Cell>Point, the CEO and has been providing financial support to the company since its beginning. Mr. Colip brings over 36 years experience in health care marketing and legal. Prior to establishing the company with Jerry Bryant and Terry Colip, Mr. Colip was a corporate mergers and acquisition lawyer and served as Deputy General Counsel for Panhandle Eastern Corporation (which has now been split with part of the company’s subsidiaries owned by Duke Energy and the remaining part owned by CMS Energy), provided legal counsel and development work for various independent power projects, served as Vice President and General Counsel for the Gulfco Division of Chromalloy American Corporation and was a production/marketing manager for the Upjohn Company (now part of Pharmacia). At Panhandle Eastern, Mr. Colip was involved in numerous complex venture, merger, spin-off and acquisition transactions including the $2.4 billion acquisition of Texas Eastern Corporation and the $1.2 billion drop down and spin-off of Anadarko Petroleum Corporation. At Upjohn, Mr. Colip was production/marketing systems manager for the corticosteroid and anticoagulant product lines. Mr. Colip received a B.S. in production management/industrial engineering in 1970, a M.B.A. in 1972 and a J.D. in 1978 from Indiana University.
Managing Member & CFO
Terry Colip is a founding member of Cell>Point, the CFO and has been providing financial support to the company since its beginning. Mr. Colip brings 26 years’ experience in health care investment banking and venture capital. Prior to the establishment of Cell>Point, Mr. Colip provided equity and investment banking services for approximately $2 billion in health care transactions and approximately $250 million in non-health care transactions. These transactions included an $85.9 million purchase of health care assets from Beverly Enterprises, Inc. and over $700 million in financings for the Voluntary Hospitals of America. Mr. Colip has worked as a health care investment banker for American Health Capital in New York, in addition to serving as Director of Health Care Finance for Boettcher & Company and Underwood, Neuhaus & Co. in Denver, Colorado. Mr. Colip also worked as a health care consultant for Coopers & Lybrand. Mr. Colip has been featured by many media outlets, including Fox Business Network, Fox News, NBC News Denver, ABC News Denver, CBS News Denver and National Public Radio. Mr. Colip received a B.S.I.E. from the College of Engineering at University of Wisconsin in 1979 and a M.P.A. in finance and health care administration from New York University in 1981. Mr. Colip dedicates his time and support to charities and organizations in health care and outreach for the disabled.
Jerry Bryant, Jr.
Managing Member & CTO
Jerry Bryant, Jr., is a founding member of Cell>Point, the CTO and has been providing financial support to the company since its beginning. Mr. Bryant brings 15 years in research experience in molecular biology, imaging and oncology. Prior to the establishment of Cell>Point, Mr. Bryant worked as a research assistant from 1994 through 1999 in the Department of Medicine, Division of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center. During 1999 and 2000, Mr. Bryant served as President of Allcure JEMA, Inc. Mr. Bryant received his B.S. from Tennessee State University in 1987 and M.S. from the University of Florida in 1991.
David Yang, Ph.D.
Vice President Research & Development
Dr. Yang brings to Cell>Point more than 30 years of pharmaceutical and fine chemicals experience. Dr. Yang received his B.S. degree in Pharmacy from Taipei Medical University in 1978. In 2007, Dr. Yang was promoted to Professor with tenure and also appointed to be the Chief of Radiotheranositc at the Division of Diagnostic Imaging at the University of Texas MD Anderson Cancer Center (UTMDACC). Dr. Yang’s research is involved in image-guided personalized treatment and prevention in cancers. Dr. Yang has mentored many clinic fellows, post-doctors, and UTGSBS students to their terminal Ph.D. degree. He received Distinguished Mentor Award for post-doctors in February, 2009 and Trainee Research Mentor Award by the MD Anderson Alumni and Faculty Association in May, 2010. He retired from UTMDACC in August, 2014. Dr. Yang holds Visiting Professor both at the Department of Radiology in Yokohama City University in Japan and Taipei Medical University in Taiwan
The Board of Advisors includes the founding partners and experts from the medical community.
Founders: Terry Colip, Greg Colip and Jerry Bryant
Wayne Yakes, M.D.
Director, Vascular Malformation Center, Interventional Neuroradiology and Interventional Radiology – Swedish Medical Center, Englewood, Colorado.
Dr. Yakes is board certified in Radiology, Interventional Radiology and Neuroradiology with thirty one clinical professor appointments with university medical centers around the world including the University Of Michigan Medical School, University of London Medical Center and Royal St. Albert’s University Medical Center. Forty eight medical publications have been authored or co-authored by Dr. Yakes in addition to five hundred and eighty five medical presentations. Dr. Yakes is a 1975 Distinguished Military Graduate and selected by Department of Army for the Military Intelligence Corps. Dr. Yakes received both his Airborne Paratrooper Badge and Ranger Tab in 1974. Dr. Yakes received his B.A. from Rice University in 1975 and M.D. from Creighton University School of Medicine in 1979.
Saad Zakko, M.D.
Consultant – Nuclear Medicine
Former Director of Department of Nuclear Medicine, Dubai Hospital
Dr. Zakko was Director of Nuclear Medicine at Dubai Hospital from 1986 through 2004. He has also served as an expert for the International Atomic Energy Agency, Vienna; Lecturer, Dubai Medical College; Member of the Editorial Board, World journal of Nuclear Medicine; Member of the International Council, American Society of Nuclear Cardiology and Adjunct Faculty Member, College of Health Sciences, Sharjah University. Dr. Zakko received his M.B.Ch.B from Bagdad Medical College and MSc. Nuclear Medicine